Human u-Plasminogen Activator (uPA)/Urokinase Antibody
Human u-Plasminogen Activator (uPA)/Urokinase Antibody Summary
Ser21-Leu432
Accession # P00749
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
u-Plasminogen Activator (uPA)/Urokinase in Human Breast Cancer Tissue. u-Plasminogen Activator (uPA)/Urokinase was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Goat Anti-Human u-Plasminogen Activator (uPA)/Urokinase Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1310) at 10 µg/mL overnight at 4 °C. Before incubation with the primary antibody tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
View Larger
u-Plasminogen Activator (uPA)/ Urokinase in Human Breast Cancer Tissue. u-Plasminogen Activator (uPA)/Urokinase was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Goat Anti-Human u-Plasminogen Activator (uPA)/Urokinase Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1310) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of immersion fixed paraffin-embedded Tissue Sections.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: u-Plasminogen Activator (uPA)/Urokinase
uPA is a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys-Pro-Gly-Arg560-Val561-Val-Gly-Gly-Cys in plasminogen to form plasmin (1). uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain, and endometrium (2). For example, the combination (both low vs. either or both high) of uPA and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), outperforms the single factors as well as other traditional prognostic factors with regard to risk group assessment for breast cancer, particularly in node-negative breast cancer (3). The human uPA is initially synthesized as 431 amino acid precursor with a N-terminal signal peptide (20 residues) (4-6). The single chain molecule is processed into a disulfide-linked two-chain molecule. The B chain starting at Ile179 corresponds to the catalytic domain. Two forms of the A chain exist, one starting at Ser21 (the long form) and the other at Lys156 (the short form). The resulting two-chain forms have different molecular weights (MW). The B chain is common for both forms whereas the long and short A chains are unique to the high and low MW forms, respectively. The long A chain contains an EGF-like domain, which is responsible for binding of the uPA receptor (uPAR). Both high and low MW forms exist in the purified recombinant human uPA.
- Ellis, V. (2004) in Handbook of Proteolytic Enzymes. Barrett, A.J. et al. eds., Academic Press, San Diego, pp.1677.
- Duffy, M.J. (2002) Biochem. Soc. Trans. 30:207.
- Harbeck, N. et al. (2002) Clin. Breast Cancer 3:196.
- Riccio, A. et al. (1985) Nucleic Acids Res. 13:2785.
- Nagai, M. et al. (1985) Gene 36:183.
- Jacobs, P. et al. (1985) DNA 4:139.
Product Datasheets
Citations for Human u-Plasminogen Activator (uPA)/Urokinase Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
5
Citations: Showing 1 - 5
Filter your results:
Filter by:
-
The Plasminogen Activator System, Glucocorticoid, and Mineralocorticoid Receptors in the Primate Endometrium During Artificial Menstrual Cycles
Authors: Esra Demirel, Reem Sabouni, Neelima Chandra, Ov D. Slayden, David F. Archer
Reproductive Sciences
-
Exosomal Annexin II Promotes Angiogenesis and Breast Cancer Metastasis
Mol. Cancer Res, 2016-10-19;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Western Blot -
An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode.
Authors: Doni A, Musso T, Morone D, Bastone A, Zambelli V, Sironi M, Castagnoli C, Cambieri I, Stravalaci M, Pasqualini F, Laface I, Valentino S, Tartari S, Ponzetta A, Maina V, Barbieri S, Tremoli E, Catapano A, Norata G, Bottazzi B, Garlanda C, Mantovani A
J Exp Med, 2015-05-11;212(6):905-25.
Species: Mouse
Sample Types: Whole Tissue
Applications: IHC -
ErbB2-enhanced invasiveness of H-Ras MCF10A breast cells requires MMP-13 and uPA upregulation via p38 MAPK signaling.
Authors: Yong HY, Kim IY, Kim JS, Moon A
Int. J. Oncol., 2010-02-01;36(2):501-7.
Species: Human
Sample Types: Cell Culture Supernates
Applications: Western Blot -
Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
Authors: Li XF, Yan PJ, Shao ZM
Oncogene, 2009-08-24;28(44):3937-48.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human u-Plasminogen Activator (uPA)/Urokinase Antibody
Average Rating: 5 (Based on 1 Review)
Have you used Human u-Plasminogen Activator (uPA)/Urokinase Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
